KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to -$117.0 million.

  • Vertex Pharmaceuticals' Cash from Investing Activities rose 66.38% to -$117.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year increase of 61.42%. This contributed to the annual value of -$3.8 billion for FY2024, which is 20.00% down from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Cash from Investing Activities stood at -$117.0 million, which was up 75.85% from -$484.5 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $175.6 million during Q4 2022, with a 5-year trough of -$2.1 billion in Q1 2024.
  • Its 3-year average for Cash from Investing Activities is -$688.1 million, with a median of -$463.7 million in 2024.
  • In the last 5 years, Vertex Pharmaceuticals' Cash from Investing Activities skyrocketed by 231.04% in 2022 and then tumbled by 3,495.29% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Cash from Investing Activities (Quarterly) stood at -$134.0 million in 2021, then soared by 231.04% to $175.6 million in 2022, then slumped by 604.84% to -$886.5 million in 2023, then increased by 7.29% to -$821.9 million in 2024, then spiked by 66.38% to -$117.0 million in 2025.
  • Its Cash from Investing Activities was -$117.0 million in Q3 2025, compared to -$484.5 million in Q2 2025 and -$55.8 million in Q1 2025.